Literature DB >> 2826783

Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands.

D L White1, P W Durbin, N Jeung, K N Raymond.   

Abstract

Chemical and biological similarities of plutonium(IV) and iron(III) suggested that octadentate ligands containing hydroxamate or catecholate functional groups, which are found in microbial iron chelating agents (siderophores), would be effective and relatively selective complexing agents for actinide(IV) ions. However, their usefulness for in vivo chelation of actinide(IV) is limited, because catechol and hydroxamate are such weak acids that the potential for octadentate binding of actinide(IV) cannot be achieved at physiological pH. The structurally similar monoprotic and more acidic 1-hydroxy-2(1H)-pyridinone (1,2-HOPO) group was, therefore, incorporated into multidentate ligands. Treatment of 1,2-dihydro-1-hydroxy-2-oxopyridine-6-carboxylic acid (5) with phosgene in THF solution gives the active ester poly[1,2-dihydro-1,2-dioxopyridine-6-carboxylate], which upon treatment with excess anhydrous dimethylamine gave a 60% yield of N,N-dimethyl-1,2-dihydro-1-hydroxy-2-oxopyridine-6-carboxamide (6). A similarly reactive intermediate was prepared from 5 and an equimolar amount of phosgene in N,N-dimethylacetamide. Combined in situ with 1,3-propanediamine, benzylamine, spermine, spermidine, 1,3,5-tris(aminomethyl)benzene, or desferrioxamine B and excess triethylamine, the latter intermediate gave the corresponding amides in isolated yields ranging from 16% to 60%. The free ligands, their Zn(II) complexes, and the ferric complex of 3,4,3-LIHOPO were administered to mice [30 mumol/kg intraperitoneally 1 h after Pu(IV)-238 citrate, kill at 24 h]. Net Pu removal [Pu excretion (treated)-PU excretion (control)], expressed as percent of injected Pu, was as follows: Na salts and Zn(II) complexes, respectively, of 3-LIHOPO (54, 56), 3,4-LIHOPO (58, 60), 3,4,3-LIHOPO (73, 76); Na salts of MEHOPO (46), DFO-HOPO (78); Fe(III) complex of 3,4,3-LIHOPO (79). DFO-HOPO and 3,4,3-LIHOPO and its Zn(II) and Fe(III) complexes promoted significantly more Pu excretion than CaNa3-DTPA (61% of injected Pu). Preliminary findings on the acute toxicity of the poly(HOPO) ligands and HOPO monomers are presented in an appendix. The biological data indicate strongly that the aqueous solubility and relatively high acidity of the octadentate HOPO ligands, 3,4,3-LIHOPO and DFO-HOPO allow them to form complete eight-coordinate complexes with Pu(IV) ion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826783     DOI: 10.1021/jm00396a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies.

Authors:  Minh Thanh La; Van Hieu Tran; Hee-Kwon Kim
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

2.  Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease models.

Authors:  Moses Q Wilks; Marc D Normandin; Hushan Yuan; Hoonsung Cho; Yanyan Guo; Fanny Herisson; Cenk Ayata; Dustin W Wooten; Georges El Fakhri; Lee Josephson
Journal:  Bioconjug Chem       Date:  2015-05-14       Impact factor: 4.774

3.  Solution thermodynamic stability of complexes formed with the octadentate hydroxypyridinonate ligand 3,4,3-LI(1,2-HOPO): a critical feature for efficient chelation of lanthanide(IV) and actinide(IV) ions.

Authors:  Gauthier J-P Deblonde; Manuel Sturzbecher-Hoehne; Rebecca J Abergel
Journal:  Inorg Chem       Date:  2013-07-16       Impact factor: 5.165

4.  Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation.

Authors:  Scott C Miller; Xuli Wang; Beth M Bowman
Journal:  Health Phys       Date:  2010-09       Impact factor: 1.316

5.  Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO).

Authors:  Rebecca J Abergel; Patricia W Durbin; Birgitta Kullgren; Shirley N Ebbe; Jide Xu; Polly Y Chang; Deborah I Bunin; Eleanor A Blakely; Kathleen A Bjornstad; Chris J Rosen; David K Shuh; Kenneth N Raymond
Journal:  Health Phys       Date:  2010-09       Impact factor: 1.316

6.  Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

Authors:  L Allott; C Da Pieve; J Meyers; T Spinks; D M Ciobota; G Kramer-Marek; G Smith
Journal:  Chem Commun (Camb)       Date:  2017-07-27       Impact factor: 6.222

7.  Identification of process related trace level impurities in the actinide decorporation agent 3,4,3-LI(1,2-HOPO): Nozzle-skimmer fragmentation via ESI LC-QTOFMS.

Authors:  Nagender R Panyala; Manuel Sturzbecher-Hoehne; Rebecca J Abergel
Journal:  J Pharm Biomed Anal       Date:  2014-08-12       Impact factor: 3.935

8.  Improved deposition and deprotection of silane tethered 3,4 hydroxypyridinone (HOPO) ligands on functionalized nanoporous silica.

Authors:  Joseph D Davidson; Robert J Wiacek; Sarah Burton; Xiaohong S Li; Glen E Fryxell; R Shane Addleman; Wassana Yantasee; Thanapon Sangvanich; Kanda Pattamakomsan
Journal:  Inorg Chem Commun       Date:  2012-04       Impact factor: 2.495

9.  Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents.

Authors:  Julian A Rees; Gauthier J-P Deblonde; Dahlia D An; Camille Ansoborlo; Stacey S Gauny; Rebecca J Abergel
Journal:  Sci Rep       Date:  2018-03-13       Impact factor: 4.379

Review 10.  Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.

Authors:  Xu Zhou; Linlin Dong; Langtao Shen
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.